Fate Therapeutics, Inc.
FATE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.05 | -0.12 | -3.92 |
| FCF Yield | -65.89% | -37.61% | -29.05% | -3.85% |
| EV / EBITDA | -1.34 | -2.50 | -3.48 | -26.17 |
| Quality | ||||
| ROIC | -51.34% | -39.73% | -51.64% | -25.49% |
| Gross Margin | 100.00% | -147.41% | 85.71% | 89.52% |
| Cash Conversion Ratio | 0.66 | 0.82 | 0.88 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -47.88% | 4.39% | 45.24% | 73.57% |
| Free Cash Flow Growth | 10.70% | 51.22% | -32.87% | -383.63% |
| Safety | ||||
| Net Debt / EBITDA | -0.28 | -0.36 | -0.16 | 0.09 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 94.76 | -83.72 | -73.42 | -480.63 |